Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients

Ping Zhang, Shilong Xiang, Bi‐Cheng Liu, Xiaohui Wang, Xiaoping Yang, Chaoyang Ye, Zunsong Wang, Yanlin Li, Li Zhou, Caili Wang, Hongbo Li, Jian Huang, Ai Peng, Xiaoping Wang, De‐Guang Wang, Jie Xiao, Wenli Chen, Hong Cheng, Nan Mao, Jianqin Wang, Lin Yang, Jianghua ChenRenal 2023 · DOI

TL;DR

This study investigated the efficacy and safety of oral nalfurafine, a kappa-opioid receptor agonist, for treating refractory pruritus (itching) in Chinese hemodialysis patients. The results demonstrated that nalfurafine, particularly at a 5 μg dose, significantly reduced itching compared to placebo, with a favorable safety profile and few adverse drug reactions, supporting its use in this patient population.

What Problem Does This Paper Address?

Chronic kidney disease-associated pruritus (CKD-aP) is a common and distressing symptom experienced by a significant percentage of patients undergoing hemodialysis. This itching can be severe and persistent, often proving refractory to conventional treatments, leading to a substantial decline in patients' quality of life, sleep disturbances, and even increased mortality risk. While previous studies, particularly in Japan, showed promise for nalfurafine in treating this condition, there was a need to confirm its efficacy and safety in a Chinese population due to potential ethnic differences that could influence drug response. This study aimed to bridge this gap by conducting a multicenter, randomized, double-blind, placebo-controlled trial in China.

Methods

This was a Phase III, multicenter, randomized, double-blind, placebo-controlled bridging study. A total of 141 Chinese patients with refractory CKD-aP were enrolled and randomly assigned in a 2:2:1 ratio to receive either 5 μg of nalfurafine, 2.5 μg of nalfurafine, or a placebo orally once daily for 14 days. The study included a 14-day pre-observation period and an 8-day post-observation period.

The primary endpoint for efficacy was the mean decrease in the Visual Analogue Scale (VAS) for itch severity from baseline. Secondary endpoints included changes in the Xie-Kawashima itch scale, improvement in sleep disorder, and the overall degree of VAS improvement. Safety was assessed by monitoring adverse drug reactions (ADRs). The study design aimed to demonstrate that the efficacy of nalfurafine in the Chinese population was comparable to that observed in the Japanese trial, specifically by meeting a predefined success criterion of at least 50% of the efficacy seen in the Japanese study.

Datasets

Not discussed in the paper. The study involved patient data collected during the clinical trial.

Key Insights and Ideas

  • Bridging Study Rationale: The study highlights the importance of "bridging studies" in drug development, allowing for the extrapolation of clinical trial data from one region to another (e.g., Japan to China) to facilitate regulatory approval without duplicating extensive research efforts, while still accounting for potential ethnic variations.
  • Nalfurafine's Efficacy in a New Population: The study successfully demonstrated that nalfurafine is effective in reducing refractory pruritus in Chinese hemodialysis patients, mirroring findings from previous Japanese trials. This suggests that the drug's mechanism of action is likely consistent across these populations for this indication.
  • Dose-Dependent Effect (Subtle): While both doses showed a reduction in VAS scores compared to placebo, the 5 μg dose achieved a statistically significant difference, suggesting a potential dose-dependent efficacy, although the 2.5 μg dose also showed a trend towards improvement.
  • Safety Profile: The study confirmed that nalfurafine has a generally favorable safety profile in this population, with the most common adverse drug reaction being insomnia. Importantly, serious adverse events were rare and not attributed to the study drug.
  • Insomnia as a Key ADR: The consistent finding of insomnia as a common ADR across nalfurafine studies warrants attention. While it didn't lead to withdrawals in this study, it was a factor in Japanese trials, suggesting it's a predictable side effect that needs management.

Key Results

  • Primary Endpoint (VAS Decrease):
    • The 5 μg nalfurafine group showed a mean VAS decrease of 11.37 mm compared to placebo (p = .041), meeting the primary endpoint and demonstrating a statistically significant reduction in itching.
  • The 2.5 μg nalfurafine group showed a mean VAS decrease of 8.81 mm compared to placebo (p = .110), which was not statistically significant but still represented an improvement.
  • Both differences exceeded the predefined success criterion of 4.13 mm, indicating at least 50% of the efficacy observed in the Japanese trial.
  • Per Protocol Set (PPS) Analysis: Similar positive results were observed in the PPS analysis, reinforcing the efficacy findings.
  • Adverse Drug Reactions (ADRs):
    • Incidence of ADRs: 49.1% in the 5 μg group, 38.6% in the 2.5 μg group, and 33.3% in the placebo group.
  • Most common ADR: Insomnia was reported in 22.8% of the 5 μg group, 14.0% of the 2.5 μg group, and 14.8% of the placebo group.
  • Other ADRs exceeding 5% included blood prolactin increase, irritability, and nausea.
  • Secondary Endpoints: While trends suggested improvement in Xie-Kawashima itch scale and sleep disorder with nalfurafine, these did not reach statistical significance in this study.

Limitations and Future Work

  • Sample Size: The study's sample size (141 patients) was smaller than the Japanese trial (337 patients), which the authors suggest might have contributed to the lack of statistical significance for the 2.5 μg dose and some secondary endpoints.
  • Subjectivity of Itch Measurement: The authors acknowledge that itch severity scales can be subjective, potentially leading to statistical discrepancies and highlighting the susceptibility of pruritus assessment to placebo effects.
  • Duration of Study: The safety and efficacy were assessed over a relatively short period (22 days). The authors suggest that longer-term studies, including Chinese patients, would be beneficial to further support the generalizability of the treatment.
  • Gender Imbalance: The study enrolled a predominantly male population, which could limit the generalizability of findings to female hemodialysis patients.
  • Future Work: The authors suggest that further investigation into longer-term efficacy and safety, as well as exploring the impact of nalfurafine on other patient populations and its potential role in managing other types of pruritus, would be valuable. Understanding the precise mechanisms behind the observed hormonal changes (e.g., prolactin) also warrants further research.

Summary updated

Abstract

<b>Background:</b> Chronic kidney disease-associated pruritus (CKD-aP) is very common and sometimes refractory to treatment in hemodialysis patients. In a trial conducted in Japan, nalfurafine, effectively reduced itching of treatment-resistant CKD-aP. Our present bridging study aimed to evaluate the efficacy and safety of nalfurafine in Chinese cohort with refractory CKD-aP.<b>Methods:</b> In this phase III, multicenter bridging study conducted at 22 sites in China, 141 Chinese cases with refractory CKD-aP were randomly (2:2:1) assigned to receive 5 μg, 2.5 μg of nalfurafine or a placebo orally for 14 days in a double-blind manner. The primary end point was the mean decrease in the mean visual analogue scale (VAS) from baseline.<b>Results:</b> A total of 141 patients were included. The primary endpoint analysis based on full analysis set (FAS), the difference of mean VAS decrease between 5 μg nalfurafine and placebo group was 11.37 mm (<i>p</i> = .041); the difference of mean VAS decrease between 2.5 μg and placebo group was 8.81 mm, but not statistically significantly different. Both differences were greater than 4.13 mm, which met its predefined success criterion of at least 50% efficacy of the key Japanese clinical trial. The per protocol set (PPS) analysis got similar results. The incidence of adverse drug reactions (ADRs) was 49.1% in 5μg, 38.6% in 2.5 μg and 33.3% in placebo group. The most common ADR was insomnia, seen in 21 of the 114 nalfurafine patients.<b>Conclusions:</b> Oral nalfurafine effectively reduced itching with few significant ADRs in Chinese hemodialysis patients with refractory pruritus.
BibTeX
@inproceedings{zhang2023randomized,
  author = {Ping Zhang and Shilong Xiang and Bi‐Cheng Liu and Xiaohui Wang and Xiaoping Yang and Chaoyang Ye and Zunsong Wang and Yanlin Li and Li Zhou and Caili Wang and Hongbo Li and Jian Huang and Ai Peng and Xiaoping Wang and De‐Guang Wang and Jie Xiao and Wenli Chen and Hong Cheng and Nan Mao and Jianqin Wang and Lin Yang and Jianghua Chen},
  title = {{Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients}},
  booktitle = {Renal},
  year = {2023},
  doi = {10.1080/0886022x.2023.2175590},
}
Figure